Viking Therapeutics, Inc. (NASDAQ:VKTX) Q3 2025 Earnings Call Transcript
Operator: Welcome to the Viking Therapeutics Third Quarter 2025 Financial Results Conference Call.
Viking Therapeutics Inc. (VKTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.15 | 1,240 | $29,942.78 | 1,240 | 2025-03-31 | Filing | |
| $24.15 | 1,240 | $29,942.78 | 1,240 | 2025-03-31 | Filing | |
| $2.47 | 45,000 | $111,195.00 | 111,250 | 2022-05-02 | Filing | |
| $5.69 | 20,000 | $113,800.00 | 66,250 | 2021-06-10 | Filing | |
| $9.82 | 9,500 | $93,260.55 | 9,500 | 2018-05-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.80 | 26,889 | $747,632.51 | 2,388,014 | 2025-07-03 | Filing | |
| $27.76 | 4,266 | $118,428.43 | 168,660 | 2025-07-03 | Filing | |
| $27.77 | 4,266 | $118,472.79 | 377,535 | 2025-07-03 | Filing | |
| $43.32 | 19,000 | $823,021.10 | 2,366,570 | 2025-01-06 | Filing | |
| $42.68 | 175,490 | $7,490,580.06 | 2,385,570 | 2025-01-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 103,447 | $2,718,588 | 0.28% | |
| 2. | 94,165 | $2,474,656 | 0.07% | |
| 3. | 76,554 | $2,011,839 | 2.53% | |
| 4. | 59,264 | $1,557,458 | 0.01% | |
| 5. | 55,930 | $1,469,840 | 0.6% |
News See All
Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best healthcare stocks with the highest upside. Viking Therapeutics, Inc.
9 Best Healthcare Stocks with the Highest Upside
Talking about how people are feeling the impact of the shutdown, Dr.
Where is Viking Therapeutics (VKTX) Headed According to Analysts?
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Joseph Pantginis reiterated a bullish stance on Viking Therapeutics, Inc.
14 Biotech Stocks with High Potential
Healthcare was the second worst performer this year, with pharma and biotech companies under pressure.
BTIG Reiterates a Buy Rating on Viking Therapeutics (VKTX) With a $125 PT
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best strong buy stocks to invest in according to Wall Street.
12 Oversold Growth Stocks to Buy According to Analysts
On September 27, Wharton professor emeritus and WisdomTree senior economist Jeremy Siegel joined CNBC for an interview to discuss the latest PCE report and what the data reveal about the market.
12 Best Strong Buy Stocks to Invest in According to Wall Street
On September 26, Peter Boockvar, chief investment officer at One Point BFG Wealth Partners, appeared on CNBC to talk about the likelihood of the Federal Reserve’s interest rate cuts, new inflation data...
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
We came across a bullish thesis on Viking Therapeutics, Inc. on Value investing subreddit by Remarkable-Ad5326. In this article, we will summarize the bulls’ thesis on VKTX.
Jim Cramer Shared Insights on These 14 Stocks
Cramer outlined a six-part framework that he uses when deciding whether to invest in a growth retailer in weakness.
Hedge Fund Resource Center Billionaire Hedge Funds
